Impact of Sodium-glucose Co-transporter 2 Inhibitors on Bone Mineral Biomarkers and Renal Progression in Diabetic Kidney Disease: A Prospective Observational Study
Indian Journal of Kidney Diseases · 2026-01 · 5 (1) · 63-68
DOI: 10.4103/ijkd.ijkd_41_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Kidney Diseases, online erschienen am 30.03.2026. Verfasst von Kajal Chaudhary und 6 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Diabetic kidney disease (DKD) is a major microvascular complication of type 2 diabetes mellitus. Although the renometabolic benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors are well established, their effects on bone mineral metabolism in DKD remain underexplored. This study prospectively evaluated changes in key bone-related biomarkers among DKD patients receiving SGLT2 inhibitors. Materials and Methods: In this prospective, open-label, hospital-based case–control study, 50 patients with type 2 diabetes and DKD (estimated glomerular filtration rate [eGFR] >30 mL/min/1.73 m 2 ) were enrolled. Forty patients received SGLT2 inhibitors (empagliflozin or dapagliflozin), and ten continued standard therapy. Baseline and 3-month assessments included glycemic indices, renal function, and bone mineral parameters – serum calcium, phosphorus, 25-hydroxy Vitamin D [25(OH) D], intact parathyroid hormone (iPTH), fibroblast growth factor 23 (FGF23), and bone mineral density (BMD).
Results
SGLT2 inhibitor therapy significantly reduced body weight, body mass index, urinary albumin-to-creatinine ratio, and eGFR. It was associated with significant increases in iPTH and FGF23, without significant changes in serum calcium, 25(OH) D, or BMD. Dapagliflozin produced a greater reduction in serum uric acid than empagliflozin ( P = 0.04).
Conclusion
SGLT2 inhibitor therapy in DKD was associated with favorable metabolic and renal effects along with hormonal alterations involving iPTH and FGF23, suggesting possible modulation of phosphate handling. These short-term findings likely reflect adaptive biochemical changes, but long-term studies are needed to determine their clinical relevance and implications for skeletal health and monitoring strategies during therapy.
Zitieren
APA
Chaudhary, K., Aslam, M., Husain, A., Ashraf, H., Raza, A., Fatima, R., & Nagvanshi, M. R. (2026). Impact of Sodium-glucose Co-transporter 2 Inhibitors on Bone Mineral Biomarkers and Renal Progression in Diabetic Kidney Disease: A Prospective Observational Study. Indian Journal of Kidney Diseases, 5(1), 63-68. https://doi.org/10.4103/ijkd.ijkd_41_25
Vancouver
Chaudhary K, Aslam M, Husain A, Ashraf H, Raza A, Fatima R, et al. Impact of Sodium-glucose Co-transporter 2 Inhibitors on Bone Mineral Biomarkers and Renal Progression in Diabetic Kidney Disease: A Prospective Observational Study. Indian Journal of Kidney Diseases. 2026;5(1):63-68. doi:10.4103/ijkd.ijkd_41_25
BibTeX
@article{Chaudhary2026,
author = {Chaudhary, Kajal and Aslam, Mohd and Husain, Amir and Ashraf, Hamid and Raza, Adil and Fatima, Razeen and Nagvanshi, Milind Raj},
title = {Impact of Sodium-glucose Co-transporter 2 Inhibitors on Bone Mineral Biomarkers and Renal Progression in Diabetic Kidney Disease: A Prospective Observational Study},
journal = {Indian Journal of Kidney Diseases},
year = {2026},
volume = {5},
number = {1},
pages = {63--68},
doi = {10.4103/ijkd.ijkd_41_25}
}
EUVIMED